Cancer Research Annual Meeting 2010  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 11, 783-787, October 1, 1951]
© 1951 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ray, F. E.
Right arrow Articles by Argus, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ray, F. E.
Right arrow Articles by Argus, M. F.

Studies on the Metabolism, Distribution, and Excretion of 2-p-Toluenesulfonamidofluorene-S35 in the Rat* ,{dagger}

Francis E. Ray and Mary F. Argus{ddagger}

( Cancer Research Laboratory, University of Florida, Gainesville, Fla.)

The distribution of radioactivity was studied in the organs and excreta of the rat at 24-, 54-, and 66-hour intervals following oral administration of a single dose of noncarcinogenic 2-p-toluenesulfonamidofluorene-S35.

The amount found in the liver (1.0 per cent) and in the blood (100 µg/100 ml plasma) was comparable to the amounts of 2-acetylaminofluorene found in similar experiments. The noncarcinogenicity of 2-p-toluenesulfonamidofluorene, therefore, is not caused by insufficient concentration of the compound in the liver (a predominant site for 2-acetylaminofluorene-induced tumors) or in the blood. Over 90 per cent of the ingested dose was found to be eliminated unchanged through the gastrointestinal tract. Only 0.5 per cent of the radioactivity was found in the urine. All the compound accounted for in the urine was in the form of 2-aminofluorene. This minute quantity of 2-p-toluenesulfonamidofluorene which undergoes metabolism contrasts with the relatively large amount, approximately 30 per cent, of the carcinogenic 2-acetylaminofluorene appearing in the urine.

* This work was supported by the Anna Fuller Fund and Public Health Cancer Research Grant C-1356.

{dagger} Presented at the Forty-second Annual Meeting of the American Association for Cancer Research, Inc., Cleveland, Ohio, April 27–29, 1951 (Abstr., Cancer Research, 11:274, 1951).

{ddagger} With the technical assistance of Gilbert Bergquist and Shyne Marley.

Received 6/ 4/51.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1951 by the American Association for Cancer Research.